Obesity Medicine is an ever-changing and advancing specialty. The 2024 edition has been reviewed and updated as of January 2024. Please see post-publishing obesity updates below, and feel free to reach out if you see something that requires review!
Updated topics, followed by the question numbers affected.
This explanation of the question mentions that there are no FDA-approved treatments for metabolic-associated steatohepatitis (MASH). Well, three months after the book's publication, the FDA approved Rezdiffra® (resmetirom) for non-cirrhotic, moderate to severe hepatic scarring.
Updated topics, followed by the question numbers affected.
Change the "A postpartum female" to "A female in her second trimester of pregnancy."
Change answer D "Abnormality to EKG" to "Abnormality to echocardiogram."
Wegovy® 2.4 mg has now received an FDA indication for reducing cardiovascular risk (major adverse cardiovascular events, including death, heart attack, or stroke) in those with known cardiovascular disease and overweight or obesity, along with lifestyle changes. [SELECT trial]. This cardiovascular benefit is mentioned in Q 323, but now there is an official FDA indication.
Please note: These newer updates are unlikely to show up on this ABOM examination test cycle.
Obesity Medicine Board Review Questions
Copyright © 2024 Obesity Medicine Board Review Questions - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.